Highlights
- Valuation Boost: Morningstar raises Pro Medicus' fair value estimate by 8% to AU$43 per share.
- Revenue Growth: FY26 revenue forecast increased to AU$275 million, reflecting a key Trinity Health contract.
- Stock Surge: Pro Medicus shares have more than doubled in value year-to-date.
Pro Medicus Ltd (ASX:PME), a leader in healthcare informatics, has received a significant valuation uplift following a major contract win with Trinity Health. Morningstar analysts have increased the company’s fair value estimate by 8% to AU$43 per share, citing a substantial boost in contracted revenue.
Contract Revenue Spurs Growth Projections
Morningstar attributes the upgraded valuation to an increase in Pro Medicus’ annualized contracted revenue, which is forecast to reach AU$62 million (USD $40.29 million) by FY26, up from a prior estimate of AU$37 million. This growth is primarily driven by the full-year earnings impact of the Trinity Health contract, a deal that highlights Pro Medicus’ competitive strength in the healthcare IT space.
The brokerage now expects Pro Medicus’ total FY26 revenue to hit AU$275 million, a 16.5% increase from its earlier projection of AU$236 million. “We assume a full-year earnings contribution in fiscal 2026, making up 15% of our total revised fiscal 2026 revenue forecast,” Morningstar noted.
Stock Performance Reflects Optimism
Pro Medicus’ shares have been on a stellar trajectory in 2024, more than doubling in value year-to-date. This robust performance underscores investor confidence in the company’s ability to secure high-value contracts and deliver sustainable growth.